两种国产rhG-CSF治疗放化疗后白细胞减少最小成本分析

Cost-minimization Analysis of Two kinds of Domestic rhG-CSF Schemes on Patients with Leukopenia after Radiotherapy and Chemotherapy

目的:比较两种国产重组人粒细胞集落刺激因子(rhG-CSF)治疗恶性肿瘤患者经放、化疗后白细胞(WBC)减少症的最小成本分析。方法:选取恶性肿瘤放、化疗后WBC减少,并采用rhG-CSF治疗的病例94例,随机分为两组,A组采用立生素治疗,B组采用瑞白治疗,WBC升至4×10~9·L^(-1)或虽未达此水平但用药已满14 d的患者,采用药物经济学最小成本分析法进行分析。结果:A、B两组成本分别为(927.0±399.0)元和(564.4±281.6)元,有统计学差异(P<0.01);总有效率分别为93.6%和91.5%,无统计学差异(P>0.05)。结论:两种国产rhG-CSF的疗效相当,但以B组的成本低,为治疗恶性肿瘤放、化疗后WBC减少的较佳药物。

Objective： To compare two kinds of domestic recombinant human granulocyte colony stimulating factor （rhG-CSF） on treatment of leucopenia after cancer by chemotherapy and radiotherapy and analyze the cost-effectiveness. Method： Ninetyfour patients of leukopenia induced by chemotherapy and radiotherapy were randomly divided into A and B two groups, A group used LiShengSu and B group used RuiBai. When WBC increased to 4×10^9·L^-1 , or even if not yet reached this level but the full 14-days drug treatment was ended, the application of pharmacoeconomics minimum cost analysis was used. Result： The cost of A, B two groups were （927.0 ±399.0） yuan and, （564.4 ± 281.6） yuan, respectively. There was statistical difference （P 〈 0.01 ）, the total efficiency were 93.6%, 91.5% respectively, there was no statistical difference（P 〉 0.05 ）. Conclusion： The effect of two domestic rhG-CSF are equal, but the cost of group B is lower and it is a better drug to treat leucopenia reduced by radiotherapy and chemotherapy.